Kadimastem Ltd (KMSTF)
USD 6.4
(0.0%)
USD 6.4
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 891.22 Thousand USD | -21.4% |
| 2022 | 1.13 Million USD | 26.73% |
| 2021 | 894.65 Thousand USD | -77.84% |
| 2020 | 4.03 Million USD | 42.49% |
| 2019 | 2.83 Million USD | 1897.57% |
| 2018 | 141.83 Thousand ILS | -72.75% |
| 2017 | 520.5 Thousand ILS | -63.26% |
| 2016 | 1.41 Million ILS | -31.0% |
| 2015 | 2.05 Million ILS | -48.37% |
| 2014 | 3.97 Million ILS | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 907.77 Thousand USD | 0.0% |
| 2023 Q4 | 891.22 Thousand USD | 0.0% |
| 2023 FY | 891.22 Thousand USD | -21.4% |
| 2022 FY | 1.13 Million USD | 26.73% |
| 2022 Q2 | 1.44 Million ILS | 0.0% |
| 2022 Q4 | 1.13 Million USD | 0.0% |
| 2021 Q2 | 4.08 Million ILS | 0.0% |
| 2021 FY | 894.65 Thousand USD | -77.84% |
| 2021 Q4 | 894.65 Thousand ILS | 0.0% |
| 2020 FY | 4.03 Million USD | 42.49% |
| 2020 Q1 | 10.94 Million ILS | 286.34% |
| 2020 Q2 | 2.69 Million ILS | -75.42% |
| 2020 Q4 | 4.03 Million USD | 0.0% |
| 2019 FY | 2.83 Million USD | 1897.57% |
| 2019 Q4 | 2.83 Million ILS | 0.0% |
| 2019 Q2 | 27.19 Thousand ILS | 0.0% |
| 2018 FY | 141.83 Thousand ILS | -72.75% |
| 2018 Q4 | - ILS | 0.0% |
| 2018 Q2 | 773 Thousand ILS | 0.0% |
| 2017 FY | 520.5 Thousand ILS | -63.26% |
| 2017 Q4 | 772 Thousand ILS | 0.0% |
| 2017 Q2 | 1.25 Million ILS | 0.0% |
| 2016 FY | 1.41 Million ILS | -31.0% |
| 2016 Q4 | 4.41 Million ILS | 0.0% |
| 2015 FY | 2.05 Million ILS | -48.37% |
| 2014 FY | 3.97 Million ILS | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 97.837% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 78.379% |
| SQZ Biotechnologies Company | 27.47 Million USD | 96.756% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 97.945% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 97.006% |
| Mesoblast Limited | 118.7 Million USD | 99.249% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 6.016% |
| Genus plc | 233.1 Million USD | 99.618% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 69.587% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 33.668% |
| Marizyme, Inc. | 18.71 Million USD | 95.239% |
| ContraFect Corporation | 2.88 Million USD | 69.065% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -18.83% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -557.794% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 38.38% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 61.683% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 84.249% |
| MultiCell Technologies, Inc. | 202.58 USD | -439837.802% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 98.45% |
| EV Biologics, Inc. | 1.49 Million USD | 40.376% |
| Q BioMed Inc. | 4.1 Million USD | 78.316% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 97.308% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -41.447% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 27.446% |
| Biomind Labs Inc. | 735.54 Thousand USD | -21.166% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.48% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 93.143% |
| Skye Bioscience, Inc. | 4.61 Million USD | 80.69% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -0.356% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -529.762% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 84.82% |
| IMV Inc. | 28.88 Million USD | 96.914% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -3365.244% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 60.537% |
| GB Sciences, Inc. | 1.75 Million USD | 49.342% |
| Alpha Cognition Inc. | 1.22 Million USD | 26.971% |
| HST Global, Inc. | 98.31 Thousand USD | -806.464% |
| CSL Limited | 12.18 Billion USD | 99.993% |
| Halberd Corporation | 150 Thousand USD | -494.151% |
| Enzolytics Inc. | 996.33 Thousand USD | 10.55% |
| Resverlogix Corp. | 6.49 Million USD | 86.27% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -86.644% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -248.691% |
| argenx SE | 20 Million USD | 95.544% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 98.044% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 67.098% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -8616.147% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.787% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -344.245% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 62.83% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -288.688% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 98.682% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 70.55% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -147.762% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 95.616% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -499.53% |
| BioStem Technologies, Inc. | 4.71 Million USD | 81.084% |
| ONE Bio Corp. | 19.71 Million USD | 95.479% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -256.231% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -258.325% |
| Agentix Corp. | 50 Thousand USD | -1682.452% |
| LadRx Corporation | 33.6 Thousand USD | -2551.985% |
| Cell Source, Inc. | 9.25 Million USD | 90.369% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -17.855% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -17.855% |
| NovAccess Global Inc. | 2.19 Million USD | 59.488% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 87.399% |
| Itoco Inc. | 228.37 Thousand USD | -290.243% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -322.432% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 82.115% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -121.781% |
| CytoDyn Inc. | 30.07 Million USD | 97.037% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -84.03% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -153.299% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 88.603% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -627.531% |
| Rebus Holdings, Inc. | 310 Thousand USD | -187.492% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 81.179% |
| International Stem Cell Corporation | 4.17 Million USD | 78.669% |
| Bioxytran, Inc. | 1.92 Million USD | 53.703% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1327.949% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 59.135% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 89.283% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 89.619% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 42.704% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -232.547% |
| Neutra Corp. | 54.15 Thousand USD | -1545.664% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 51.299% |
| PureTech Health plc | 25.51 Million USD | 96.507% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 27.201% |
| IXICO plc | 472.02 Thousand USD | -88.81% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 94.251% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 98.569% |
| CSL Limited | 12.18 Billion USD | 99.993% |
| Cellectis S.A. | 92.77 Million USD | 99.039% |